Andrew Technologies, based in Haddonfield, NJ, is a medical company focused on revolutionizing diabetes care and restoring health. They are currently conducting a clinical trial to improve glycemic control in patients with type 2 diabetes using their patented HydraSolve T2D System, which safely removes mesenteric visceral fat to improve diabetes management and reduce the risk of long-term complications.
With diabetes being a global epidemic, Andrew Technologies aims to provide a surgical alternative to address this widespread disease. Their innovative approach has shown promising results in a pre-clinical non-human primate study, where insulin resistance was reversed and weight loss achieved without dietary restrictions. The company is now recruiting patients for their pilot trial, with the goal of improving the lives of individuals with type 2 diabetes.
Generated from the website